NCT04088396
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
StatusActive, Not Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 102 versions: 37 with changes below, 13 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Primary and study completion pushed from Sep 2026 to Oct 2026
- Site details revised at 55 of 55 sites
- Minor Site details revised at 5 of 55 sitesv100
- Minor Site details revised at 16 of 55 sitesv99
- Minor Study sites: 56 to 55v98
- Minor Study sites: 57 to 56
- Primary and study completion dates pushed to Sep 2026
Show 32 earlier versionsHide 32 earlier versions
- Minor Site details revised at 1 of 57 sitesv96
- Minor Study sites: 58 to 57v95
- Minor Site details revised at 1 of 58 sitesv94
- Minor Site details revised at 40 of 58 sitesv92
- Minor Study sites: 59 to 58v91
- Minor Study sites: 67 to 59v90
- Minor Site details revised at 2 of 67 sitesv89
- Minor Study sites: 65 to 67v87
- Minor Eligibility criteria expanded, about 10 wordsv86
- Minor Primary completion date: Oct 2025 to Apr 2026
- Study completion date: Oct 2025 to May 2026
- Eligibility criteria revised
- Minor Study sites revised (65)v84
- Minor Site details revised at 2 of 65 sitesv83
- Minor Study sites: 64 to 65v82
Notable Enrollment target: 103 to 58v81 Show 8 more changesShow less
- Primary endpoint revised
- Study sites: 65 to 64
- Primary and study completion dates: Oct 27, 2025 to Oct 2025
- Interventions: Baricitinib (Drug), Placebo (Drug) to Baricitinib (Drug), Tocilizumab (Drug)
- Eligibility criteria expanded, about 49 words
- Secondary endpoints: 8 to 7
- Study arms: 2 to 3
- Study title expanded, about 4 words
- Minor Study sites: 21 to 65v80
- Minor Study sites: 65 to 21v78
- Notable Primary and study completion dates: Aug 7, 2023 to Oct 27, 2025
- Study sites: 67 to 65
- Minor Study sites: 66 to 67v76
- Minor Site details revised at 2 of 66 sitesv75
- Minor Site details revised at 2 of 66 sitesv66
- Minor Site details revised at 1 of 66 sitesv65
- Minor Site details revised at 1 of 66 sitesv64
- Minor Study sites: 69 to 66v63
- Minor Site details revised at 2 of 69 sitesv62
- Minor Site contacts updated at 1 of 69 sitesv60
- Minor Study sites: 68 to 69v59
- Minor Study sites: 67 to 68v58
- Minor Study sites: 66 to 67v57
- Minor Study sites: 65 to 66v56
- Minor Site contacts updated at 1 of 65 sitesv55
- Minor Eligibility criteria shortened, about 61 words
- Site contacts updated at 2 of 65 sites
- Minor Study sites revised (65)v53
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12
Timeframe: Week 12
Secondary (7)
Percentage of Participants Achieving Adapted PediACR30 Response Criteria at Week 24
Percentage of Participants with Inactive Disease
Percentage of Participants with Minimal Disease Activity
Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27
Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
Show 2 moreShow less
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)
PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss)
Arms and interventions
Cohort 1 BaricitinibExperimental
Baricitinib given orally.
Cohort 1 TocilizumabActive comparator
Tocilizumab given Subcutaneously (SC).
Cohort 2 BaricitinibExperimental
Baricitinib given orally.
Drugs: Baricitinib, Tocilizumab
Sites
55 sites in 14 countries
Italy 8, Japan 7, Spain 6, Brazil 5, France 5, Mexico 5, United Kingdom 5, Israel 3, Poland 3, Argentina 2, Czechia 2, Turkey (Türkiye) 2, Belgium 1, India 1